Niagen Bioscience, Inc.
NAGE
$10.14
$0.15651.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.12M | 30.48M | 29.13M | 25.58M | 22.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.12M | 30.48M | 29.13M | 25.58M | 22.74M |
| Cost of Revenue | 10.89M | 11.15M | 10.93M | 9.34M | 9.05M |
| Gross Profit | 20.23M | 19.33M | 18.20M | 16.24M | 13.69M |
| SG&A Expenses | 15.47M | 13.30M | 9.77M | 13.35M | 12.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.93M | 25.71M | 22.01M | 23.98M | 23.00M |
| Operating Income | 3.19M | 4.77M | 7.11M | 1.60M | -256.00K |
| Income Before Tax | 3.74M | 5.23M | 7.48M | 1.88M | -15.00K |
| Income Tax Expenses | 128.00K | 168.00K | 305.00K | -- | -- |
| Earnings from Continuing Operations | 3.61M | 5.06M | 7.18M | 1.88M | -15.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.61M | 5.06M | 7.18M | 1.88M | -15.00K |
| EBIT | 3.19M | 4.77M | 7.11M | 1.60M | -256.00K |
| EBITDA | 3.38M | 4.97M | 7.30M | 1.80M | -49.00K |
| EPS Basic | 0.05 | 0.07 | 0.09 | 0.02 | 0.00 |
| Normalized Basic EPS | 0.03 | 0.04 | 0.06 | 0.02 | 0.00 |
| EPS Diluted | 0.04 | 0.06 | 0.09 | 0.02 | 0.00 |
| Normalized Diluted EPS | 0.03 | 0.04 | 0.06 | 0.02 | 0.00 |
| Average Basic Shares Outstanding | 79.25M | 77.81M | 76.95M | 75.97M | 75.56M |
| Average Diluted Shares Outstanding | 86.24M | 83.23M | 81.68M | 77.77M | 75.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |